STADA has recenty expanded its presence in nephrology beyond biosimilars to provide an innovative treatment for kidney health. Through a strategic partnership established in 2022, STADA secured the first European approval for a treatment for a rare kidney disease immunoglobulin A nephropathy (IgAN). This treatment benefits a small and under-served patient population and is classified as an “orphan drug” with a market exclusivity period of 10 years.
In line with STADA’s purpose of Caring for People’s Health as a Trusted Partner, the group continues to explore opportunities to develop and market further medicines in nephrology.
